

## COMPOUNDS INDUCING DEGRADATION OF THE CELLULAR PRION PROTEIN

**The patent** stems from the collaborative work of a team of researchers with established expertise in computational biophysics, neurobiology and medicinal chemistry. The patent covers in particular different classes of compounds inducing the degradation of the cellular prion protein, a membrane glycoprotein involved in deadly communicable neurodegenerative diseases known as prion diseases. The project is ready to move to hit to lead phase.

### OPPORTUNITY

The different classes of compounds are described in priority filing IT102020000006517. Biotech and pharma companies, as well as investors (venture capital) interested in learning more about the patent and in discussing its exploitation can contact Fondazione Telethon Business Development Office (tto@telethon.it) by October 15<sup>th</sup>, 2020.

### References:

- Spagnoli, et al. **Pharmacological Protein Inactivation by Targeting Folding Intermediates**. BioRxiv, doi:<https://doi.org/10.1101/2020.03.31.018069> (2020)
- Biasini, et al. **Prion protein at the crossroads of physiology and disease**. Trends Neurosci 35, 92-103, doi:10.1016/j.tins.2011.10.002 (2012).